Estudios Clínicos

En esta sección encontrará los estudios clínicos más recientes, los cuales avalan la calidad, eficacia y efectividad de los principios activos de nuestros medicamentos.

ADA 2023 Chronic Kidney Disease and Risk Management
ADA 2023 Cardiovascular Disease and Risk Management
ADA 2023 Classification and Diagnosis
ADA 2023 Glycemic Targets
ADA 2023 Pharmacologic Approaches
Management of Hyperglycemia ADA EASD 2022
Revista ALAD V5N1
Diabetic Agents, From Metformin
EMPA KIDNEY
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Empare reduced en español JACC
EMPULSE
Gliflozins From Antidiabetic Drugs to Cornerstone in Heart
Safety of Empagliflozin in
SGLT2 Inhibitors Statins or ACE Inhibitors of the 21st Century
The EMPEROR Reduced Trial
The role of SGLT2 I in vascular aging
Cardiorenal Syndrome Classification Pathophysiology Diagnosis and Treatment Strategies A Scientific Statement From the American Heart Association
KDIGO 2022
Management of Heart Failure in Patients with Chronic Kidney Disease
Synopsis KDIGO 2022
Use of Glucose Lowering Agents
2022 AHA ACC HFSA Guideline for ICC resumen
Guía ESC 2021 Full text
Guía manejo ICC AHA full text
Iacoviello – Recent advances in pharmacological treatment of heart failure
ADA 2023 Pharmacologic Approaches
Docherty PARADIGM HF2
PARADIGM-HF
PARAGON HF
PIONEER HF
TITRATION
TRANSITION Study